Available via license: CC BY 4.0
Content may be subject to copyright.
Received 08/16/2024
Review began 09/06/2024
Review ended 09/25/2024
Published 10/11/2024
© Copyright 2024
Tufail et al. This is an open access article
distributed under the terms of the Creative
Commons Attribution License CC-BY 4.0.,
which permits unrestricted use, distribution,
and reproduction in any medium, provided
the original author and source are credited.
DOI: 10.7759/cureus.71278
Comparing Holotranscobalamin and Total
Vitamin B12 in Diagnosing Vitamin B12
Deficiency in Megaloblastic Anemia Patients
Noareen Tufail , Muzammil Kataria , Ahmed Jamal Chaudhary , Rubaid A. Dhillon ,
Muhammad Asif Naveed , Shahida Mohsin
1. Haematology, University of Health Sciences, Lahore, PAK 2. Internal Medicine, Jinnah Hospital, Lahore, PAK 3.
Internal Medicine, Detroit Medical Center (DMC) Sinai-Grace Hospital, Detroit, USA 4. Internal Medicine, Riphah
International University, Rawalpindi, PAK 5. Pathology, University of Health Sciences, Lahore, PAK
Corresponding author: Rubaid A. Dhillon, rbazhar@hotmail.com
Abstract
Background
Megaloblastic anemia is characterized by abnormally large red blood cells caused by a deficiency in either
vitamin B12 or folic acid, both of which are essential for DNA synthesis. Vitamin B12 insufficiency can lead
to severe neurological damage, making early identification of vitamin B12 deficiency crucial to prevent
irreversible harm. Vitamin B12 deficiency results in decreased levels of holotranscobalamin (Holo-TC) and
increased levels of methylmalonic acid (MMA). Methylmalonic acid is considered the gold standard for
diagnosing B12 deficiency because it is a specific marker that rises when B12 is insufficient, even when
serum B12 levels appear normal. Elevated MMA levels reflect impaired B12 metabolism, making it a critical
tool for early detection and intervention. Previous research indicates that Holo-TC, the active form of
vitamin B12 available to cells, is a more specific diagnostic tool for early vitamin B12 deficiency than total
B12. This study aims to determine the diagnostic validity of total vitamin B12 and Holo-TC using MMA as
the gold standard in patients with megaloblastic anemia.
Methods
A total of 95 megaloblastic anemia patients were selected from Jinnah Hospital and Lahore General Hospital,
Lahore, Pakistan, after receiving approval from the ethical review committees. This was a cross-sectional
study. Whole blood, serum, and urine samples were collected in ethylenediamine tetraacetic acid (EDTA)
vials, gel vials, and urine containers, respectively. The EDTA samples were used for complete blood count
measurements using a hematology analyzer (Sysmex-XT 1800i, Sysmex America, Inc., Mundelein, IL), while
serum and urine samples were employed for the detection of serum folic acid, cobalamin, Holo-TC, and
MMA levels through manual enzyme-linked immunosorbent assay (ELISA) techniques. Sensitivity,
specificity, positive predictive value (PPV), and negative predictive value (NPV) of Holo-TC and cobalamin
were calculated.
Results
The majority of patients fell within the age group of 20-70 years, with 57% of them being females and 43%
males; Holo-TC exhibited a sensitivity of 98.9% and specificity of 50.00%, with a PPV of 98.90% and NPV of
50%. Vitamin B12 demonstrated a sensitivity of 63% and specificity of 50%, with a PPV of 98.33% and NPV
of 2.85%. The diagnostic accuracy of Holo-TC and vitamin B12 was observed to be 97.8% and 63%,
respectively.
Conclusions
Between the two, Holo-TC displays higher diagnostic accuracy than vitamin B12 and can serve as the
primary test for patients suspected of having vitamin B12 deficiency.
Categories: Epidemiology/Public Health, Internal Medicine, Hematology
Keywords: diagnostic accuracy, holotranscobalamin, megaloblastic anemia, methylmalonic acid, vitamin b12
Introduction
Megaloblastic anemia comprises a group of disorders resulting from defective DNA synthesis and nucleus-
cytoplasmic asynchrony, leading to anemia characterized by abnormally large red blood cells [1]. This
condition can cause a variety of symptoms due to the impaired production of red blood cells. Both vitamin
B12 and folate are crucial for DNA synthesis, and a deficiency in either or both of these vitamins can cause
megaloblastic anemia [2]. Among these, vitamin B12 deficiency stands out as a major leading cause of
megaloblastic anemia. Inadequate dietary intake, overcooking of food, and poor absorption can contribute
to vitamin B12 deficiency, leading to a higher incidence of the condition in populations with these risk
1 2 3 4
5 1
Open Access Original Article
Published via Global Remote Research
Scholars Program
How to cite this article
Tufail N, Kataria M, Chaudhary A, et al. (October 11, 2024) Comparing Holotranscobalamin and Total Vitamin B12 in Diagnosing Vitamin B12
Deficiency in Megaloblastic Anemia Patients. Cureus 16(10): e71278. DOI 10.7759/cureus.71278
factors. The incidence of megaloblastic anemia increases in countries with prevalent malnutrition, where
routine vitamin supplementation is not available for vulnerable groups such as the elderly and pregnant
women [3]. The presentation of megaloblastic anemia can vary among individuals, but common symptoms
include fatigue, weakness, shortness of breath, loss of appetite, weight loss, fast heartbeat, a smooth or
tender tongue, numbness and tingling in extremities, ataxia, and cognitive impairment [4]. These symptoms
result from the body's inability to produce enough healthy red blood cells, which impairs oxygen delivery to
tissues.
In Pakistan, megaloblastic anemia is frequently encountered in clinical practice, and vitamin B12 deficiency
is common in the Pakistani population. For example, a study observed vitamin B12 deficiency in 72.6% of
the study population [5]. Another study by Naeem and Uttra (2007) found vitamin B12 deficiency in 31.8% of
the population, while a study by Nizamani et al. (2014) reported the prevalence of B12 deficiency at 57% [6,
7]. A study by Devrajani et al. (2011) observed a prevalence of vitamin B12 deficiency at 48%. These statistics
underscore the significant burden of B12 deficiency in Pakistan [8].
Methylmalonic acid (MMA) serves as a specific marker of vitamin B12 deficiency [9]. Both MMA and
homocysteine levels increase in cases of vitamin B12, B6, and folate deficiency [8]. Previous literature has
demonstrated that cobalamin and folate deficiency can be differentiated by measuring MMA and
homocysteine levels. Homocysteine levels are elevated in cases of folate deficiency, whereas MMA levels are
predominantly elevated in cobalamin deficiency [10]. This differentiation is important for accurate diagnosis
and treatment.
Holotranscobalamin (Holo-TC), an active fraction of cobalamin, serves as a sensitive marker with a
sensitivity of 93.33% and specificity of 80% [11]. It is superior and an early marker for detecting changes in
vitamin B12 status within the body compared to total vitamin B12 levels [12]. Holotranscobalamin represents
biologically available B12 since it is utilized by cells for various functions such as DNA synthesis, providing
insight into early changes in B12 levels. Low serum Holo-TC levels indicate insufficient vitamin B12 stores.
Low serum Holo-TC and high MMA levels indicate B12 deficiency [13]. This marker is particularly helpful in
cases where there is no correlation between vitamin B12 levels and its metabolites. Various suitable methods
are now available to measure Holo-TC [14].
Therefore, it is essential to diagnose early or subclinical cases of cobalamin deficiency before irreversible
neurological damage occurs. The present study aimed to evaluate cobalamin deficiency using newly
established parameters like Holo-TC with MMA as the proxy gold standard. The results of these patients will
also be compared with already established parameters like vitamin B12 levels. While total vitamin B12 levels
may miss patients with vitamin B12 deficiency, Holo-TC appears to be a more sensitive marker, supporting
its use as a primary parameter for detecting cobalamin deficiency. This approach could improve early
diagnosis and treatment, preventing severe complications.
Materials And Methods
A cross-sectional study was conducted in the Department of Hematology, University of Health Sciences
(UHS), Lahore, Pakistan, following the approval of the study synopsis by the Advanced Studies Research
Board of the UHS (approval number: UHS/ERC/23/118). A sample size of 95 was determined using health
studies software (version 2.0.21 WHO, Geneva, Switzerland) with a 6% margin of error, a 95% confidence
level, and an anticipated sensitivity of Holo-TC of 90%. The participants were selected through non-
probability/consecutive sampling.
Inclusion and exclusion criteria
The inclusion criteria comprised adult patients of either sex aged 20-70 years with hemoglobin levels of less
than 12 g/dL for males and less than 10 g/dL for females and a mean corpuscular volume (MCV) greater than
100 fl along with hyper-segmented neutrophils. Patients who were already receiving vitamin B12 therapy,
taking multivitamins, undergoing blood transfusion therapy, had a history or diagnosis of chronic illnesses
such as hypothyroidism, cardiac diseases, gastrointestinal disorders, pulmonary tuberculosis, or liver
disease, were experiencing folate deficiency, or had a history of alcohol intake were excluded from the study.
Sample collection and laboratory analyses
After obtaining written consent from the patients, sample data were collected. A total of five milliliters of
venous blood was drawn from each patient for the determination of the complete blood count (CBC) and
peripheral smear morphology examination. Additionally, serum levels of folate, vitamin B12, Holo-TC, and
urine MMA were measured using the enzyme-linked immunosorbent assay (ELISA) technique. Urine samples
were collected in urine sampling jars for the measurement of urinary MMA levels.
In the laboratory, CBCs were performed using Sysmex XT 1800i (Sysmex America, Inc., Mundelein, IL) on
collected ethylenediaminetetraacetic acid (EDTA) samples, and peripheral smears were prepared and
examined under a microscope. One aliquot was used for serum B12, a second for serum folate, and the third
aliquot was used for serum Holo-TC. Urine samples were used for MMA level measurements. Serum folate,
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 2 of 7
cobalamin, Holo-TC, and MMA levels were determined using the ELISA technique. Details regarding the
reagents, including the specific brands and concentrations used, the equipment, such as the Sysmex XT-
1800i hematology analyzer, and the ELISA kits employed for serum folate, vitamin B12, Holo-TC, and MMA
measurements, have been included to enhance the reproducibility of the analysis.
Statistical analyses
All statistical analyses were performed using IBM SPSS Statistics software, version 20.0, Armonk, NY.
Descriptive statistics were used to summarize the baseline characteristics of the study participants,
including age and gender distribution. Continuous variables were presented as means ± standard deviations
(SD), and categorical variables were presented as frequencies and percentages.
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of Holo-TC and
cobalamin were calculated with corresponding 95% confidence intervals (CIs). Comparative analyses were
conducted using chi-square tests for categorical variables and independent t-tests for continuous variables.
A regression analysis was performed to assess the relationship between Holo-TC and MMA levels, as well as
between vitamin B12 and MMA levels. The coefficients, standard errors, and p-values were calculated to
determine the significance of these relationships. The level of significance was set at a p-value < 0.05, and
all p-values were two-tailed. Diagnostic accuracy was calculated for vitamin B12 and Holo-TC with MMA as
the proxy gold standard. The study aimed to determine the diagnostic validity of total vitamin B12 and
Holo-TC in detecting B12 deficiency in patients with megaloblastic anemia, with MMA serving as the
reference standard.
Results
Out of the total 95 megaloblastic anemia patients, 54 (57%) were female and 41 (43%) were male, falling
within the age group of 20-70 years.
To assess normal distribution, the Shapiro-Wilk test was applied, revealing that Hb, red blood cell (RBC)
count, MCH, folate, and MMA levels exhibited a normal distribution with p-values ≥ 0.05. The mean values
for Hb, RBC count, mean corpuscular hemoglobin (MCH), folate, and MMA were 7.4 ± 2.1 g/dL, 3.08 ± 0.7 ×
10^6/µL, 28.4 ± 3.6 pg, 420.8 ± 168.2 ng/mL, and 50.9 ± 16.6 ng/mL, respectively.
In contrast, age, MCV, mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count,
platelets, vitamin B12, and Holo-TC parameters did not follow a normal distribution with p-values ≤ 0.05.
The median with interquartile range (IQR) levels for these parameters were as follows: age = 37 (24) years,
MCV = 110 (12) fl, MCHC = 31 (5) g/dL, WBC count = 4.1 (3.1) × 10^3/µL, platelet count = 120 (60) × 10^3/µL,
B12 level = 201 (496) ng/L, and Holo-TC level = 0.16 (2.06) ng/mL (Table 1).
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 3 of 7
Variables Mean ± SD Median (IQR) P-value Data distribution
Age (years) 38.9 ±13.8 37 (24) 0.000 Not normal
Hb (g/dl) 7.4 ± 2.1 7.5(3.4) 0.127 Normal
RBC count (X106/ul) 3.08 ± 0.7 3.1(0.9) 0.342 Normal
MCV (fl) 109 ± 6.3 110 (12) 0.000 Not normal
MCH (pg) 28.4 ± 3.6 29(5) 0.057 Normal
MCHC (g/dl) 31.2 ± 2.9 31 (5) 0.027 Not normal
WBC count (X103/µl) 5.0 ± 2.7 4.1 (3.1) 0.000 Not normal
Platelet count (X103/l) 130 ± 72 120 (60) 0.000 Not normal
Vitamin B12 level (ng/L) 417 ± 500 201(496) 0.000 Not normal
Folate (ng/ml) 420.8 ± 168.2 460(256) 0.079 Normal
Holo-TC (ng/ml) 1.88 ±4.0 0.16 (2.06) 0.000 Not normal
MMA (ng/ml) 50.9 ± 16.6 50.7(20.43) 0.852 Normal
TABLE 1: Data distribution of the study population
Hb: hemoglobin; RBC: red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin
concentration; WBC: white blood cell; Holo-TC: holotranscobalamin; MMA: methylmalonic acid
Oval macrocytosis and hyper-segmented neutrophils were present in the peripheral blood of all 95 (100%)
patients. Folate levels were elevated in all 95 (100%) selected patients. Among the 95 megaloblastic patients,
33 (34.7%) had very low, 14 (15%) had low, 14 (15%) had borderline low, 30 (31%) had normal, and four
(4.3%) had high levels of B12.
The diagnostic accuracy of serum Holo-TC and serum B12 was quantified by measuring sensitivity,
specificity, PPV, and NPV (Table 2). The sensitivity, specificity, PPV, and NPV were calculated using MMA as
the proxy gold standard. The sensitivity of Holo-TC and B12 was found to be 98.9% and 63%, respectively.
Specificity for both Holo-TC and B12 was observed to be 50%. The PPV for Holo-TC and B12 was 98.91% and
98.33%, respectively. The NPV for serum Holo-TC and serum B12 was 50% and 2.85%, respectively. The
diagnostic accuracy of serum Holo-TC was calculated to be 97.87%, while that of serum cobalamin was
63.15%.
Parameters Sensitivity, % Specificity, % PPV,% NPV,% Diagnostic accuracy
Serum B12 63 50 98.33 2.85 63.15
Serum Holo-TC 98.9 50 98.91 50 97.87
TABLE 2: Diagnostic performance of holotranscobalamin and serum B12 having methylmalonic
acid as gold standard
Holo-TC: holotranscobalamin; PPV: positive predictive value; NPV: negative predictive value
A regression analysis was conducted to further investigate the relationship between B12, Holo-TC, and MMA
levels (Table 3). The coefficient for B12 was found to be 0.04, suggesting a slight positive association with
MMA levels; however, the borderline significance indicates minimal impact. The coefficient for Holo-TC was
found to be -1.20, indicating a significant negative association with MMA levels. Higher Holo-TC levels are
associated with lower MMA levels. This analysis supports the findings from Table 2 that Holo-TC is a more
sensitive and reliable marker for B12 deficiency.
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 4 of 7
Predictor variables Coefficient (β) Standard error (SE) t-value p-value 95% CI lower 95% CI upper
Constant 45.2 3.4 13.290.00038.5 51.9
Vitamin B12 level (ng/L)0.04 0.02 2.000.0480.00 0.08
Holo-TC (ng/mL) -1.20 0.58 -2.070.042-2.35 -0.05
TABLE 3: Regression analysis of holotranscobalamin and vitamin B12 against methylmalonic
acid levels
Holo-TC: holotranscobalamin Discussion
Megaloblastic anemia is a hematological disorder characterized by megaloblastic changes in the bone
marrow due to a defect in DNA synthesis. These changes result in the production of abnormally large and
immature red blood cells, which are less effective at transporting oxygen throughout the body. The condition
arises primarily from deficiencies in vitamin B12 and folic acid, both of which are essential for DNA
synthesis and red blood cell formation. Numerous studies have highlighted the substantial burden of
micronutrient deficiency, with vitamin B12 and folic acid deficiencies being the most significant
contributors to megaloblastic anemia [15]. This highlights the critical need for proper nutritional intake to
prevent such deficiencies.
The current study utilized MMA as the gold standard to evaluate the diagnostic validity of total vitamin B12
and Holo-TC in patients with megaloblastic anemia. Methylmalonic acid is a specific marker for vitamin B12
deficiency; its levels increase when vitamin B12 is insufficient.
Our study comprised 57.0% females, predominantly in the age group of 20-70 years. This finding aligns with
observations from several prior studies that reported a higher prevalence of vitamin B12 deficiency among
females compared to males [7, 16, 17]. Factors such as inadequate dietary intake, overcooking of food, poor
absorption, and low socioeconomic status likely contribute to vitamin B12 insufficiency in our community.
Additionally, specific life stages and conditions, such as pregnancy and lactation, may further
impact vitamin B12 levels in females, making them more susceptible to deficiency [18].
To better understand the vitamin B12 status of our patients, we stratified megaloblastic anemia patients
based on their vitamin B12 levels into five groups: very low, low, borderline low, normal, and high levels.
Among the 95 patients, 34.7% had very low levels, 14.7% had low levels, 14.7% had borderline low levels,
31.6% had normal levels, and 4.3% had high levels of B12. The p-value for this distribution was 0.000,
indicating a significant variation in vitamin B12 levels among the patients. Our results align with those of
Nizamani et al. (2014), who categorized vitamin B12-deficient patients into similar groups [7]. Interestingly,
4.3% of patients in our study exhibited high vitamin B12 levels, which corresponds to the findings of a study
where 5.6% of patients had elevated vitamin B12 levels due to underlying myeloproliferative disorders [19].
In our study, we made efforts to rule out diseases such as hypothyroidism, cardiac diseases, gastrointestinal
disorders, pulmonary tuberculosis, and liver disease, all of which can elevate vitamin B12 levels. By focusing
on a specific patient group with megaloblastic anemia, the study provides targeted insights that are highly
relevant for clinical practice in diagnosing and managing this condition. The study adds valuable data to the
limited research on diagnostic markers for megaloblastic anemia in Pakistan, contributing to the
understanding of vitamin B12 deficiency in this population. Additionally, we attempted to ascertain whether
patients had recently taken B12 supplementation. However, many patients were not well educated and
belonged to a low socioeconomic class, making it challenging to obtain this information. For patients
presenting with symptoms of B12 deficiency, investigations may reveal elevated serum cobalamin levels,
accompanied by an increase in MMA levels. This functional cobalamin deficiency may arise due to increased
binding of vitamin B12 to haptocorrin, leading to a reduction in the delivery of B12 to peripheral cells [20].
Relying solely on serum B12 assays can result in up to a 50% misdiagnosis rate [16]. Serum cobalamin levels
may fall within the normal range in patients with clinical signs of cobalamin deficiency. Therefore, tests
such as serum Holo-TC and MMA levels are appropriate next steps to rule out vitamin B12 deficiency.
Low Holo-TC levels indicate vitamin B12 deficiency. Our study results demonstrated that Holo-TC levels
were low in all patients (n = 94), except for one patient who had normal Holo-TC levels. High MMA levels
indicate vitamin B12 deficiency. Present study results demonstrated that 93 (97.9%) patients had elevated
MMA levels, while only two patients showed normal MMA levels. Our study showed a sensitivity of 98.9% for
Holo-TC, with a specificity of 50.00%. The PPV was 98.91%, and the NPV was 50%. Conversely, the
sensitivity of vitamin B12 was 63%, with a specificity of 50%, a PPV of 98.33%, and an NPV of 2.85%. The
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 5 of 7
diagnostic accuracy of HoloTC was observed to be 97.8%, while that of vitamin B12 was 63.15%. Our study
results are consistent with those of previous studies [11, 13, 21], all of which found Holo-TC to be a more
sensitive marker for detecting B12 deficiency than serum B12 levels.
Our study revealed a high prevalence of vitamin B12 deficiency in younger populations, with 36.8% falling in
the 20-30-year age group. This finding is in line with observations by a study that reported a 45% prevalence
of B12 deficiency in the 21-40 age group [15]. Additionally, our study showed that non-vegetarians were
more likely to experience vitamin B12 deficiency, with 84% of patients being non-vegetarian. These results
align with a study where the frequency of vitamin B12 deficiency in vegetarians was 78.5%, compared to 85%
in non-vegetarians [18].
The current study was constrained by a small sample size due to financial limitations. Future research
should consider larger sample sizes to enhance the diagnostic specificity of Holo-TC. Additionally, the
availability of MMA testing is limited, and both cobalamin and MMA levels can fluctuate over time in
ambulatory care settings, which may not predict cobalamin-responsive diseases. Nonetheless, Holo-TC
appears to be a superior test for identifying vitamin B12 deficiency, and this study contributes to the limited
research on diagnostic markers for megaloblastic anemia in Pakistan. To facilitate its integration into
routine diagnostic workflows, clinicians could adopt a stepwise approach: initially testing patients with
symptoms of vitamin B12 deficiency using Holo-TC as a primary screening tool, followed by MMA testing for
borderline or ambiguous cases. Regular monitoring of high-risk populations, such as the elderly and those
with malabsorption syndromes, using Holo-TC could further improve early detection and treatment
outcomes. These recommendations align with the growing body of evidence supporting Holo-TC as a more
sensitive marker than total B12.
Conclusions
In conclusion, our study found that Holo-TC is a more sensitive marker than serum cobalamin levels for
detecting vitamin B12 deficiency, with a sensitivity of 98.9%, specificity of 50.00%, PPV of 98.90%, and NPV
of 50%. Conversely, vitamin B12 exhibited lower sensitivity (63%), specificity (50%), PPV (98.33%), and NPV
(2.85%). The diagnostic accuracy of HoloTC was 97.8%, while that of vitamin B12 was 63.15%. Our study
emphasizes the importance of Holo-TC as an effective tool for identifying vitamin B12 deficiency and
suggests its use as a primary diagnostic parameter. Further research with larger sample sizes and diverse
populations is recommended to validate these findings and to explore the integration of Holo-TC testing
into routine clinical workflows.
Additional Information
Author Contributions
All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the
work.
Acquisition, analysis, or interpretation of data: Rubaid A. Dhillon, Muzammil Kataria, Muhammad Asif
Naveed, Shahida Mohsin
Critical review of the manuscript for important intellectual content: Rubaid A. Dhillon, Ahmed Jamal
Chaudhary
Concept and design: Ahmed Jamal Chaudhary, Noareen Tufail
Drafting of the manuscript: Noareen Tufail, Muzammil Kataria, Muhammad Asif Naveed, Shahida
Mohsin
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Advanced Studies
Research Board of University Health Sciences, Lahore issued approval (UHS/ERC/23/118). Animal subjects:
All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.
References
1. Green R, Datta Mitra A: Megaloblastic anemias: nutritional and other causes . Med Clin North Am. 2017,
101:297-317. 10.1016/j.mcna.2016.09.013
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 6 of 7
2. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV: Anaemia in low-income and middle-
income countries. Lancet. 2011, 378:2123-35. 10.1016/S0140-6736(10)62304-5
3. Darnton-Hill I, Mkparu UC: Micronutrients in pregnancy in low- and middle-income countries . Nutrients.
2015, 7:1744-68. 10.3390/nu7031744
4. Obeagu EI, Babar Q, Obeagu GU: Megaloblastic anaemia-a review . Int J Curr Res Med Sci. 2021, 7:17-24.
5. Ahmed T, Rahman AS, Ahmed S, Siddiqui A, Javed A, Kamal J, Ahmed L: Frequency of vitamin B12 and red
cell folate deficiency in macrocytic anaemia. J Basic Appl Sci. 2012, 8:06-13. 10.6000/1927-
5129.2012.08.02.68
6. Naeem MA, Uttra GM: Etiology of increased incidence of megaloblastic anaemia in district gilgit . Pak J
Pathol. 2007, 18:15-26.
7. Nizamani GS, Memon IA, Memon A, Khoharo HK: Vitamin B12 deficiency with megaloblastic anemia: an
experience at tertiary care hospital of sindh. Journal of Liaquat University of Medical & Health Sciences.
2014, 13:13-20.
8. Devrajani BR, Zaman SM, Shah SZ, Devrajani T, Lohana RK, Das T: Helicobacter pylori: a cause of vitamin
B12 deficiency (a hospital based multidisciplinary study). World Applied Sci J. 2011, 3:78-81.
9. Fragasso A, Mannarella C, Ciancio A, et al.: Holotranscobalamin is a useful marker of vitamin B12 deficiency
in alcoholics. ScientificWorldJournal. 2012, 2012:128182. 10.1100/2012/128182
10. Yetley EA, Pfeiffer CM, Phinney KW, et al.: Biomarkers of vitamin B-12 status in NHANES: a roundtable
summary. Am J Clin Nutr. 2011, 94:313S-21S. 10.3945/ajcn.111.013243
11. Jarquin Campos A, Risch L, Nydegger U, et al.: Diagnostic accuracy of holotranscobalamin, vitamin B12,
methylmalonic acid, and homocysteine in detecting B12 deficiency in a large, mixed patient population. Dis
Markers. 2020, 2020:7468506. 10.1155/2020/7468506
12. Bamonti F, Moscato GA, Novembrino C, et al.: Determination of serum holotranscobalamin concentrations
with the AxSYM active B(12) assay: cut-off point evaluation in the clinical laboratory. Clin Chem Lab Med.
2010, 48:249-53. 10.1515/CCLM.2010.032
13. Herrmann W, Obeid R: Holotranscobalamin: an early marker for laboratory diagnosis of vitamin B12
deficiency. Euro Haematol. 2009, 3:7-11. 10.17925/EOH.2009.03.1.7
14. Nexo E, Hoffmann-Lücke E: Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and
clinical utility. Am J Clin Nutr. 2011, 94:359S-65S. 10.3945/ajcn.111.013458
15. Sivaprasad M, Shalini T, Balakrishna N, et al.: Status of vitamin B12 and folate among the urban adult
population in South India. Ann Nutr Metab. 2016, 68:94-102. 10.1159/000442677
16. Palacios A, Hurley K, Ponce SD, et al.: Zinc deficiency is associated with anemia among children under 24
months-of-age in rural Guatemala (P10-111-19). Curr Dev Nutr. 2019, 3:nzz034.P10-111-19.
10.1093/cdn/nzz034.P10-111-19
17. Valente E, Scott JM, Ueland PM, Cunningham C, Casey M, Molloy AM: Diagnostic accuracy of
holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B₁₂ status
in the elderly. Clin Chem. 2011, 57:856-63. 10.1373/clinchem.2010.158154
18. Iqbal SP, Kakepoto GN, Iqbal SP: Vitamin B12 deficiency--a major cause of megaloblastic anaemia in
patients attending a tertiary care hospital. J Ayub Med Coll Abbottabad. 2009, 21:92-4.
19. Al Aisari F, Al-Hashmi H, Mula-Abed WA: Comparison between serum holotranscobalamin and total
vitamin B12 as indicators of vitamin B12 status. Oman Med J. 2010, 25:9-12. 10.5001/omj.2010.3
20. Shipton MJ, Thachil J: Vitamin B12 deficiency - a 21st century perspective . Clin Med (Lond). 2015, 15:145-
50. 10.7861/clinmedicine.15-2-145
21. Heil SG, de Jonge R, de Rotte MC, et al.: Screening for metabolic vitamin B12 deficiency by
holotranscobalamin in patients suspected of vitamin B12 deficiency: a multicentre study. Ann Clin Biochem.
2012, 49:184-9. 10.1258/acb.2011.011039
Published via Global Remote Research
Scholars Program
2024 Tufail et al. Cureus 16(10): e71278. DOI 10.7759/cureus.71278 7 of 7
